Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Operating Leases (2020 - 2026)

Lexaria Bioscience's Operating Leases history spans 6 years, with the latest figure at $62326.0 for Q1 2026.

  • Quarterly results put Operating Leases at $62326.0 for Q1 2026, down 49.62% from a year ago — trailing twelve months through Feb 2026 was $62326.0 (down 49.62% YoY), and the annual figure for FY2025 was $109319.0, changed 0.0%.
  • Operating Leases for Q1 2026 was $62326.0 at Lexaria Bioscience, down from $70819.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $123723.0 in Q1 2025 to a low of $18339.0 in Q2 2022.
  • The 4-year median for Operating Leases is $101920.0 (2024), against an average of $82381.2.
  • The sharpest move saw Operating Leases tumbled 73.01% in 2022, then changed 0.0% in 2025.
  • Year by year, Operating Leases stood at $18339.0 in 2022, then surged by 455.76% to $101920.0 in 2024, then plummeted by 30.52% to $70819.0 in 2025, then fell by 11.99% to $62326.0 in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $62326.0, $70819.0, and $109319.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.